Spotlight – Travere trips up but others are following in rare kidney disease
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Spotlight – following Humira in hidradenitis suppurativa
Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
Spotlight – Vertex flexes its dealmaking muscle
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?
Spotlight – What's next in Nash
The next few months will see some important mid-stage Nash results, from Viking, 89Bio, Northsea and others.
Spotlight – Cystic fibrosis developers take a deep breath
The next couple of years should show whether inhaled genetic projects have potential.
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
Spotlight – still plenty of hopefuls in lung fibrosis
Roche’s zinpentraxin alfa is out of the running, but Bristol, Blade, Pliant and others have contenders in the mid-stage idiopathic pulmonary fibrosis pipeline.
